On Target Laboratories
4065 Commercial Avenue
18 articles with On Target Laboratories
Intraoperative Molecular Imaging of Non-Small Cell Lung Cancer Improves Outcomes for 26 Percent of Patients in Multi-Institutional Phase 2 Clinical Trial
OTL38 Receives FDA Fast Track Designation for Lung Cancer as it Begins Phase 3 Clinical Trials
On Target Laboratories, Inc., a privately held biotechnology company that is developing tumor-targeted imaging agents to improve cancer surgery, announced today the appointment of Kimberly Fabrizio as Vice President of Regulatory and Quality.
Journal Reports OTL38 Reveals Undetected Cancer in 48% of Patients
On Target Laboratories, Inc., a privately held biotechnology company that is developing tumor-targeted fluorescent imaging agents to improve cancer surgery, announced today that it has completed its Phase 2, multi-center, open-label clinical trial for OTL38 in the detection of lung cancer nodules in lung cancer patients during surgery.
8/16/2019Biopharma companies strengthen their executive ranks and boards with new additions.
On Target Laboratories Announces Leadership Transition and Appoints Christopher Barys as Chief Executive Officer
On Target Laboratories, Inc., a privately held biotechnology company that is developing tumor-targeted imaging agents to improve cancer surgery, today announced that Christopher Barys has joined the company as Chief Executive Officer and will join the board of directors.
On Target Laboratories, Inc. announced the appointment of Donna Haire as Executive Vice President of Regulatory and Quality.
On Target Laboratories Announces Amendment to Ongoing Phase 3 Trial Expanding Camera System Compatibility
On Target Laboratories, Inc. announced that the protocol for the company's Phase 3 clinical trial, OTL38 for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer, has been amended to allow the use of Quest Medical Imaging's Spectrum® Platform camera system.
On Target Laboratories Announces Publication Supporting Use of OTL78 to Highlight Prostate Cancer Lesions
On Target Laboratories, Inc. announced today the publication of a study evaluating the effectiveness of On Target Laboratories' drug, OTL78, in highlighting malignant lesions during radical prostatectomies.
9/25/2018Ovarian cancer is the fifth leading cause of cancer-related deaths in the United States. It is estimated that this year there will be more than 22,000 women in the U.S. diagnosed with the disease and about 14,000 disease-related deaths.
On Target Laboratories announced that the first patient was treated in its Phase III trial of OTL38 in detecting ovarian cancer. Linked with a near-infrared dye, OTL38 allows surgeons to visually identify cancer cells that can guide them in removing the cancer tissue.
The randomized, multi-center, single dose, open label, pivotal Phase 3 study in patients with ovarian cancer will assess the efficacy of OTL38 to identify additional ovarian cancer lesions not detectable by current means.
On Target Laboratories Raises Additional Capital from H.I.G. BioHealth Partners, Elevate Ventures and Helsinn
These recent raises bring the total financing round close to $44 million.
The company will use the funding to further develop its lead imaging compound, OTL38, for use in detecting multiple cancers.
On Target Laboratories Release: Funding Milestone Reached For 'Light Up' Cancer Cell Research In Both Lung And Ovarian Cancer